Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 9, 2013, Pages 1943-1950

  Tielbeek, Jeroen A W ^a   Löwenberg, Mark ^a   Bipat, Shandra ^a   Horsthuis, Karin ^a   Ponsioen, Cyriel Y ^a   D'Haens, Geert R ^a   Stoker, Jaap ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Biological therapy; Crohn's disease; MR enterography; Therapeutic monitoring

Indexed keywords

ADALIMUMAB; ENEMA; GADOLINIUM; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SCOPOLAMINE BUTYL BROMIDE;

ADULT; ANTIINFLAMMATORY ACTIVITY; CLINICAL ARTICLE; CONFERENCE PAPER; CROHN DISEASE; DIAGNOSTIC ACCURACY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MONITORING; ENTERITIS; FEMALE; HUMAN; INTESTINE ENDOSCOPY; LABORATORY TEST; MAGNETIC RESONANCE ENTEROGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PROGNOSIS; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884668297     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182905536     Document Type: Conference Paper

References (32)

1. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
2. D'Haens GR, Fedorak R, Lémann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009;15:1599-1604.
3. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
4. Samuel S, Bruining DH, Loftus EV, et al. Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol. 2012;10:1253-1259.
5. Dignass A, van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohn Colitis. 2010;4:28-62.
6. Hyun SB, Kitazume Y, Nagahori M, et al. Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's disease. Inflamm Bowel Dis. 2011;17:1063-1072.
7. Horsthuis K, Bipat S, Stokkers PCF, et al. Magnetic resonance imaging for evaluation of disease activity in Crohn's disease: a systematic review. Eur Radiol. 2009;19:1450-1460.
8. Higgins PD, Caoili E, Zimmermann M, et al. Computed tomographic enterography adds information to clinical management in small bowel Crohn's disease. Inflamm Bowel Dis. 2007;13:262-268.
9. Bruining DH, Siddiki HA, Fletcher JG, et al. Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis. 2012;18:219-225.
10. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17: 1415-1422.
11. Hara AK, Alam S, Heigh RI, et al. Using CT enterography to monitor Crohn's disease activity: a preliminary study. AJR Am J Roentgenol. 2008;190:1512-1516.
12. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-2284.
13. Sauer CG, Kugathasan S, Martin DR, et al. Medical radiation exposure in children with inflammatory bowel disease estimates high cumulative doses. Inflamm Bowel Dis. 2011;17:2326-2332.
14. Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology. 2008;247:64-79.
15. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. Inflamm Bowel Dis. 2011;17:1073-1080.
16. Punwani S, Rodriguez-Justo M, Bainbridge A, et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology. 2009;252:712-720.
17. Ziech ML, Bossuyt PM, Laghi A, et al. Grading luminal Crohn's disease: which MRI features are considered as important? Eur J Radiol. 2012;81: e467-e472.
18. Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn's disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis. 2011;17:984-993.
19. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;6736:1-16.
20. Steward MJ, Punwani S, Proctor I, et al. Non-perforating small bowel Crohn's disease assessed by MRI enterography: Derivation and histopathological validation of an MR-based activity index. Eur J Radiol. 2012;81: 2080-2088.
21. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
22. Ziech ML, Lavini C, Caan MW, et al. Dynamic contrast-enhanced MRI in patients with luminal Crohn's disease. Eur J Radiol. 2012;81: 3019-3027.
23. Bruining DH, Loftus EV, Ehman EC, et al. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:679-683.
24. Negaard A, Paulsen V, Sandvik L, et al. A prospective randomized comparison between two MRI studies of the small bowel in Crohn's disease, the oral contrast method and MR enteroclysis. Eur Radiol. 2007;17:2294-2301.
25. Fiorino G, Bonifacio C, Padrenostro M, et al. A prospective comparison between 1.5T magnetic resonance and 3T magnetic resonance in ileocolonic Crohn's disease: a single center experience. Gastroenterology. 2011;140:S695-S695.
26. Rimola J, Ordás I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759-1768.
27. Tielbeek JA, Makanyanga J, Bipat S, et al. Grading Crohn's disease activity with MRI: Interobserver variability of MRI features, MRI scoring of severity and correlation with Crohn's Disease Endoscopic Index of Severity. Am J Roentgenol. DOI: 10.2214/AJR.12.10341. In press.
28. Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-a and thiopurine therapy for crohn's perianal fistulas. Inflamm Bowel Dis. 2012;18:1825-1834.
29. Bruining DH, Sandborn WJ. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:395-399.
30. Jones J, Loftus E V, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224.
31. Cipriano LE, Levesque BG, Zaric GS, et al. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis. 2012;18:1240-1248.
32. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4: 1017-1024; 976.